Linkingmed

Based in Beijing, Linkingmed operates at the intersection of artificial intelligence and oncology, specializing in radiotherapy solutions. The company was founded in March 2016 by Ryan Hua Zhang, who holds a Ph.D. from the Netherlands Cancer Institute and has a background that includes academic visits to Microsoft Research Asia and the University of California, San Diego. His journey began with a focus on using information technology to create scalable cancer treatments, an idea that evolved into the founding of Linkingmed. The firm secured its initial angel investment of 12 million RMB in August 2016 after entering the Microsoft Venture Capital Accelerator.

Linkingmed develops and provides a cancer data analysis platform designed to assist medical institutions in analyzing oncology data. Its business model is centered on offering technical tools and cloud services to hospital radiotherapy departments and third-party imaging and radiotherapy centers on a B2B basis. The company generates revenue by selling its products and services, with an average price of around CNY 1.2 million, tailored to the traffic of the purchasing hospital. Its clients are primarily medical staff, including doctors, researchers, and physicists who use the platform to digitally review and issue cancer treatment plans.

The core of Linkingmed's offering is its suite of AI-powered radiotherapy cloud services, which includes tools for automatic organ contouring (AiContour), treatment auto-planning (AiPlan), and quality control (AiQA). A key feature is the ability to significantly reduce the time required for an oncologist to contour a tumor's target location from several hours to approximately 20 minutes, while also improving accuracy. The platform also facilitates remote collaboration, allowing specialists to serve patients in different locations. Its RAIC·OIS (Oncology Information System) and the AiContour system have received NMPA Class III medical device certification, marking their official commercialization. The company has raised a total of $15.3M in funding and has attracted investments from firms such as Grains Valley Venture Capital, Binhai Venture Capital, and Linear Capital Partners.

Keywords: radiotherapy AI, oncology data analysis, medical imaging, cancer treatment planning, cloud-based radiotherapy, automatic contouring, treatment auto-planning, radiotherapy quality control, medical data platform, teleradiology, HealthTech, oncology, decision analysis, artificial intelligence, machine learning, RAIC OIS, AiContour, AiPlan, Ryan Hua Zhang, Beijing startup